Plus   Neg

Eli Lilly Reports Positive Results From Selpercatinib Trial - Quick Facts

Eli Lilly And Co. (LLY) reported positive data from the LIBRETTO-001 trial intended to support the registration of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer. The study showed 68 percent objective response rate and sustained durability. Selpercatinib was well-tolerated in the study.

Josh Bilenker, interim senior vice president of oncology research and early phase development at Lilly, said: "We look forward to submitting the NDA later this year, and should selpercatinib receive regulatory approval, patients with RET fusion-positive NSCLC will finally have their first genomically-guided medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products. Hundreds of Facebook employees staged a "virtual walkout" on Monday to protest the company's decision not to act on recent controversial posts by President Donald Trump on the social media platform. The employees criticized Facebook chief executive Mark Zuckerberg's decision to not moderate a post from Trump last Thursday.
Follow RTT